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1. Introduction 
Radiotherapy (RT) in its different forms –distance, contact, intraoperative - currently is a 
powerful means of damaging cancer cells. RT is used both, as a radical monotherapy and in 
combination with different radiosensitizers or antitumor chemotherapeutic agents. The 
main problem of radiotherapy is the inevitable effect of ionizing radiation on normal tissues 
that results in unwanted side effects. Solving this problem was achieved practically by 
improvement of technical capacities of the ionizing radiation source and planning systems 
of irradiation procedure. The up-to-date therapeutic devices combine capacities of a medical 
imaging system (computed tomography) with a radiation therapeutic device. The 
combination according to the "two-in-one" principle ensures not only an ideal guiding of 
radiation on the target, but also constantly corrects the guiding, taking into consideration 
displacement of the target in the process of the patient's breathing, etc. The up-to-date 
planning systems help to increase reliability of precise guiding of ionizing radiation. Thus, 
unwanted action of ionizing radiation on normal tissues is reduced to the minimum, but is 
not excluded completely. In the last 100 years RT has transformed into a separate powerful 
trend in medicine. RT is equipped with sophisticated therapeutic devices widely used in 
oncological clinical practice - about 70% of oncological patients need these or those variants 
of RT. What are the prospects of the further improvement of RT? Obviously, the further 
technical improvement of therapeutic devices cannot be considered as a single way of RT 
development. 
1.1 Binary radio therapy: What is it? 
The most real trend of RT development is the development and introduction into clinical 
practice of Binary radiotherapy (BRT). Currently it is possible to speak about two types of 
BRT. They are neutron capture therapy (NCT), the idea of which was proposed in 1936 
(Locher, 1936) and photon capture therapy (PCT). In English scientific literature is used the 
term "photon activation therapy". The principles of NCT and PCT (Khokhlov, 2004) are very 
similar. A malignant tumor is saturated with a preliminarily administered agent containing 
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an element which is highly capable of interacting with the particular external ionizing 
radiation. Then tumor distant irradiation is carried out and local release of energy directly in 
the target tumor takes place. The main task is to make the total dose in the tumor to be lethal 
for its cells, and radiation exposure of normal tissues not to exceed the limits of their 
radiotolerance. Ideally, this permits to replace sophisticated technical devices for guiding 
ionizing radiation into the tumor with self targeting system based on biological or 
pharmacokinetic principles, and to increase considerably specificity and therapeutic 
effectiveness of radiation treatment technology. It is this circumstance that is the main 
impetus initiating research in this direction. For implementation of BRT two components are 
needed - a source of ionizing radiation (flow of neutrons or photons of certain energy) and 
pharmaceutical which composition includes the elements being highly capable of interaction 
with ionizing radiation. 
1.2 Physic principals of binary radio therapy 
The basis of BRT are the physical processes occurring as a result of interaction of certain 
elements, being constituents of composition of special pharmaceuticals, with external ionizing 
radiation. Let us consider in more details peculiarities of BRT taking as an example boron 
neutron capture therapy (BNCT), gadolinium neutron capture therapy (GdNCT) and PCT. 
10B-Neutron Capture Therapy (BNCT) is based on nuclear reaction 10В(n,,)7Li occurs as the 
result of interaction between stable isotope 10B with thermal neutron (Еn=0.025 eV). That 
interaction has very high probability (σ=3890 barn). Also as the result of the following 
nuclear reaction high energy short range charged particles – nucleus of helium (α-particle) 
and nucleus of lithium are emitted. These particles has high linear energy transfer (LET) to 
tissue (200 keV for α-particle and 350 keV for lithium nucleus) and short path length (about 
14 μm) comparable to the diameter of a single cell. Such charged particles are equally lethal 
for oxygenated cells, hypoxic cells and cells in G0-stage. Sub lethal and potentially lethal 
damages caused by this kind of particles are nonreparable unlike the damages induced by 
the photon radiation. That is why BNCT is the most effective in treating tumors with cells 
are highly capable for DNA reparation. i.e. melanoma and glioblastoma. And if selective 
accumulation of 10B in tumor cells is provided then selective radiation exposure could be 
achieved on the cell level: only tumor cells with 10B inside would be destroyed leaving 
healthy tissues undamaged, thus killing all indefinitely small metastasis. In theory BNCT 
could overcome major limitations of photon radiotherapy: too high radioresistance of some 
tumor cells and to low radiotolerance of normal tissues. 
For successful implementation of BNCT in clinical practice a complex of complicated chemical, 
medical, biological, physical and engineering problems must be solved. The most important 
task of them is development of 10B-containing drug capable to deliver necessary therapeutical 
amount of 10B into malignant tumor cells providing 10B optimum intracellular distribution for 
a time necessary for neutron irradiation. It was calculated that for a fluence of 1013 n/cm2 
concentration of 10B should be about 20-35 μg/g or 109 atoms of 10B per cell. To prevent 
damage of healthy tissues in the irradiated volume there must be at least 3 times less 
concentration of 10B in them than in the tumor tissue. The requirement of the 10B amount in the 
tumor cell depends greatly on it’s intracellular localization. It’s assumed that 2 μg/g of 10B is 
enough for successful BNCT in case of it’s localization inside the cells nuclei. Therefore the 
radiobiological efficacy of 10В(n,,)7Li reaction greatly depends on so called “factor of 
compound” provided by peculiarities of chemical structure of boron with main substance, it’s 
metabolism and it’s distribution among the most important organelles of the tumor cell. 
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After many years of purposeful searches, two compounds were selected for BNCT - 
mercaptoundecahydrododecaborate (Sivaev, 2002) - Na2B12H11SH (BSH) and p-
(dihydroxybor)-L-phenylalanine (BPA) (Snyder, 1958). As the clinical experience has shown, 
these compounds are not optimal for BNCT, but nevertheless it is possible to use BSH rather 
successfully at the combined treatment of brain tumors with BNCT (Japan, USA, countries 
of EU), and BPA - at the treatment of skin melanoma and its metastases (Japan, USA). 
Clinical trials are being conducted to study effectiveness of BNCT with BPA in treating 
brain tumors (Japan, USA). A parallel intensive scientifically grounded search of new, more 
perfect, boron-containing compounds for BNCT is going on. 
An important aspect of the effective conduction of BNCT is also the existence of the methods 
which are capable to provide the optimal individual planning and control of its conduction. 
First of all, it is necessary to know the absolute concentration of 10B, its microdistribution in 
the process of irradiation, that will allow to choose correctly the time of irradiation, to 
enhance accuracy of dosimetry and microdosimetry, thereby determining success of BNCT. 
In this connection of particular value is the development and mastering in clinical setting of 
the neutron radiation method of determining boron in tumor and normal tissues in real time 
by (n,)-reaction to 10B, and also a number of other analytical methods allowing to determine 
intracellular concentration and location of boron, such as quantitative autoradiography of 
high performance, electron spectroscopy and others. Up to the present the evaluation of 
boron concentration in tumor at BNCT is conducted as a rule on the basis of preliminarily 
obtained data, for example, during surgical operation for removal of brain tumor, or 
indirectly - by the blood level of boron taking into account also preliminarily established 
ratio of its concentrations tumor/blood. 
Interaction of photon radiation with different elements is characterized by dominating in a 
particular energy range (Fig. 1) of photon absorption by heavy elements (with Z≥53) on 
absorption by light elements composing biological tissues (H, O, N, C, Na, K, Cl etc.). This 
difference can be used for local increasing of energy absorption in the target (tumor) by 
administration or accumulating some heavy element in necessary region of irradiation. 
 
 
Fig. 1. Energy dependence of specific photon kerma for the basic elements of biological 
tissue and some heavy elements (Sheino, 2006). 
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In terms of Radiotherapy such approach can be implemented by administration or 
accumulation in a tumor volume the necessary amount of a pharmaceutical containing some 
heavy element with subsequent irradiation of the tumor region with X-rays of certain 
energy spectrum. As the result of such irradiation local increase of absorbed dose in the 
tumor occurs. In case of necessary amount of heavy element in the target is provided the 
increase of absorbed dose can be 2-3 times higher than for the same irradiation but with no 
drug administered (Karnas, 1999; Sheino, 2006). Emission of short range radiation caused by 
photoabsorption on heavy elements directly in the irradiated target is effective factor of 
tumor cell growth suppression. Significant that in PCT absorbed dose in healthy tissues 
could be lower than it’s tolerant dose. Thus radiation influence on healthy tissues is 
decreasing and selectivity of tumor tissue damage is increasing during irradiation 
procedure. Such binary technology was called Photon Capture Therapy. Combination of 
biological self targeting of radiation and it’s main localization in target volume makes PCT 
prospective Radiotherapy technology. 
 
 
Fig. 2. Relative increase of a dose in a biological tissue for various elements with Z>53 at 
their concentration of 1% in dependence on energy of photons. (Sheino, 2006). 
Calculated estimation show (Sheino, 2006) that proper therapeutic efficacy of PCT could be 
achieved if the concentration of heavy element is around ~ 10 mg/g. At present there are no 
drugs with i.v. administration capable to accumulate in tumor tissues in such amount. That 
is why gadolinium containing MRI-contrast pharmaceutical Dipentast® (Russia) and 
intratumoral way of administration were used in our primary studies of PCT. 
1.3 Tasks of research 
The chapter presents the results of the preclinical studies on BRT conducted in Russia. 
Melanoma was chosen as the main object of the research. The studies were carried out in 
conformity with the effective RF requirements for three main directions: 1. the studies on the 
В-16 mouse melanoma cell culture; 2. the studies of mice with the transplanted B-16 
melanoma; the studies on dogs with spontaneous B-16 melanoma. The similarity of canine 
and human melanomas permitted to replace the transplanted nude melanomas with the 
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model of canine spontaneous melanoma. The chapter presents the used neutron and photon 
bundles. It presents the main characteristics of the used pharmaceutical products with 10В 
([10В]-boron phenylalanine in the pharmaceutical form borate ether with D-fructose; [10В]-
BSH - mercapto-closo-undecaborateas a sodium salt (Sivaev, 2002) and gadopentetat in the 
pharmaceutical form ensuring delayed elimination of the substance from the injection site). 
The results of remote consequences of BRT and traditional methods of melanoma treatment 
- surgical intervention, immune therapy, action of ionizing radiation (neutrons and gamma-
radiation) are given. The comparison of therapeutic effectiveness of NCT with 10В and Gd 
used as both monotherapy and in combination with adjuvant immune therapy with 
interleukin-2 (Roncoleukin) is presented. Separately there are presented the results of the 
micropharmacokinetic studies - distribution of BSH and a number of new boron-containing 
agents across the main organelles of melanoma cell. For the results beyond the scope of the 
preclinical studies, the references to the published works are given.  
2. Materials and methods 
2.1 Irradiation of biological objects 
Neutron irradiation was performed on the irradiation facilities of Moscow Engineering and 
Physics Institute research reactor IRT and research reactor RR-8 of RRC “Kurchatov 
Institute”. The IRT facility includes the irradiation room for positioning cell cultures and 
laboratory animals including dogs in the neutron beam. The neutron beam delivered to the 
irradiation room has the following characteristics: thermal neutron flux – 1.1×109 n/cm2s, 
fast neutron flux – 5.8×107 n/cm2s, photon dose rate - 1.8×10-4 Gy/s. Irradiation room is 
equipped with video surveillance to observe the state of irradiation object and with the 
physiological parameters monitoring system (heart and breath frequency, blood pressure, 
body temperature ) as well as with drug delivery system. IR-8 reactor facility is designed for 
irradiation small object only - cell cultures and small animals. Thermal neutron flux on IR-8 
facility was 1.2×108 n/cm2s, fast neutron flux – less than 0.96×107 n/cm2s, photon dose rate - 
8.3×10-7 Gy/s. Small animals were not anesthetized prior the irradiation. At the IR-8 animals 
were irradiated in Teflon® cages, at IRT animals were situated in lead boxes, which were 
limiting animal’s movements but not interfering feeding and defecations. Local irradiation 
of transplanted into the rear paw tumor immobilized in advance was performed with dose 
of 2.5 Gy-Eq. Considering that poor fluence power thermal neutron irradiation was 
prolonged for time individual group as control for each animal group was used. 
X-rays irradiations were performed using radiobiology autoprotective X-rays facility with 
anode voltage 220 kV and dose rate at the position of cell culture monolayer 2.0 Gy/min for 
cell culture irradiation and X-rays irradiation of mice bearing B-16 melanoma was 
performed with an X-ray unit with anode voltage of 150 kV and dose rate of 0.7 Gy/min at 
treated tumor volume. 
2.2 Dosimetry  
Thermal neutron absorbed dose at NCT was measured with prompt gamma neutron 
activation analysis (PGNAA). Average dose in tissue without drug was 0.25 Gy/h. Total 
absorbed dose was determined by 3 nuclear reactions, which provide the major part of 
absorbed dose (95-97%) during interaction of thermal neutrons with nuclides of biological 
tissue - 1H (n,γ)2H; 14N (n,p)14C; 10B (n,α)7Li.  
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Dose rate of X-rays in irradiation position was performed using DKS-AT5350/1 dosimeter 
(Russia) and dosimetric films Gafchromic® EBT. Optical density of dosimetric films was 
measured on Varian Cary-50 spectrophotometer. 
2.3 Animals and cell culture 
B-16 melanoma cell culture for experiments was received from Blockin’s Cancer Research 
Center (Russia) storage. These cells were grown as monolayer in glass flasks containing 
mixture of RPM6-1640 and Eagle’s nutrient media with 10% calf serum and gentamicyne. 
Grown cells were suspended in saline. Cell concentration in suspension was 1000 per 1 ml.  
Cultural flasks in PCT in vitro studies were divided to experimental and control groups. 
Both groups were irradiated using X-rays with 10 Gy, 20 Gy, 30 Gy and 40 Gy. Before 
irradiation Dipentast® was added into experimental flasks for 0.2 mg/ml Gd concentration.  
Experiments in vivo were conducted on ǿ57Bl/6 male and female mice bearing 
subcutaneously transplanted melanoma В-16. All mice were of veterinary certification.  
The mice were subcutaneously inoculated into rear paw with (3.5-4)106 melanoma cells. All 
NCT and PCT experiments were conducted 10-11 days after transplantation (tumor volume 
was about 0.9-1.0 ȟm3).  
For NCT studying the mice were injected intraperitoneally with saline solutions of KUG-1 
and BSH in amount of 0.2 ml containing 150 mg of boron per kg body weight for BSH and 
25 mg of B per kg body weight for KUG-1. After injection of studied compounds ( in 6 hours 
for BSH and in 24 hours for KUG-1) tumor was locally irradiated.  
For PCT the animals were divided into four groups: 1- experimental group irradiated with 
X-rays and administered with Gd-DTPA before irradiation, 2 – mice only locally irradiated 
with X-rays but not injected with Gd-DTPA, 3 – nonirradiated mice but only administered 
with Gd-DTPA with the same amount that the experimental group, 4 – untreated mice. 
When tumor volume was achieved 1 ȟm3 1 and 3 animal groups were intratumorally 
administrated with 0.175 ml Dipentast®. After administration mice from 1 group were 
immediately irradiated with X-rays in 20 Gy dose. 
For NCT studies Dogs with spontaneous oral cavity melanoma were selected in LLC 
“Biocontrol” based on the results of clinical examination. The owners of the dogs were 
agreed on experimental treatment.  
60 dogs with oral cavity melanoma were selected for the study . The dogs were examined 
before and after treatment using clinical and histological methods. The dogs were divided 
on the following groups: I group – without treatment; II group – surgical treatment; III – 
distant gamma-therapy, IV group – neutron therapy; V – BNCT; VI - GdNCT ; VII – 
Complex treatment (NCT with adjuvant immunotherapy with Ronkoleukine); VIII group 
– NCT without immunotherapy. BNCT was performed with [10В]-BPA in pharmaceutical 
form of boron ether solution with D-fructose. GdNCT was performed with Dipentast®. 
In V group BPA were administered by two routes: in the artery which nourish tumor and 
intravenously (Fig. 3). Administration of the medicine was controlled by X-ray examination. 
Irradiation was performed 2.0-2.5 hours after BPA administration 
2.4 Cell vitality assessment 
For cell vitality assessment after irradiation MTT-test (Mosman, T., 1983) and clonogenic test 
were used. For MTT-test cells were sewed in 96-holes flat-bottomed plates and incubated 
during 3, 5, 7 days. 2-3 hours before termination 10 μl of (4,5-dimethylthiazoline-2)-2,5 
diphenyltetrazoly bromide (final concentration was 1 mg/ml). After incubation cells were 
www.intechopen.com
 Binary Radiotherapy of Melanoma - Russian Research Results 
 
129 
centrifuged at 1200 rev/min during 7-10 min. Supernatant was carefully removed. 200 μl of 
DMSO were added into each hole for formazane solution. Optical density of homogenous 
solution was determined in “Picon” photometer at 530 nm. Optical density of solution was 
demonstration of redox-intensivity in cell culture. For clonogenic test cells of both groups 
were sewed in 6-holes plates with full medium and in 3, 5, 7 days cell colonies were count 
using LOMO microscope. 
 
  
Fig. 3. Preclinical trials of BNCT in dogs with spontaneous malignant melanoma. Infusion of 
BPA drugs using a feeding pump (left); X-ray control of the compound administration 
(richt).  
2.5 Quantification of boron and gadolinium 
Boron tumor concentration was measured in vivo with PGNAA (Khokhlov, 2008; Khokhlov, 
2009). During irradiation this concentration in tumor varied about 7-8 μg/g for [10B]-BSH, 
10-20 μg/g for ВǾА and 10-11 μg/g for KUG-1. 
Gd tumor concentration varied about 10-100 mg/ȟm3, Gd concentration in biological 
samples was measured with neutron-activation analysis (Zaitsev, 2004 а) or using roentgen 
fluorescent analysis in X-Art-Ǻ concentration analyzer (Comita Ltd, Russia). 
2.6 Subcellular boron distribution 
In 5 min., 1 and 24 h after BSH, KUG-1 administration experimental tumors were excised, 
rinsed, weighed and homogenized. The cell organelles were prepared using routine 
techniques of differential centrifugation (De Duve, 1967). 
Subcellular fractions (nuclei, mitochondria, lysosomes, cytosol) were received for further 
boron determination with PGNAA method. 
2.7 Study of kinetics of B-16 melanoma cell population 
Kinetics of B-16 melanoma cell population was studied at determination of melanocytes and 
DNA-synthesizing cells percentage in total studied tumor cells. 
For this purpose tumors of exponential growth phase were used. On 7-th day after 
subcutaneous inoculation experimental ǿ57BL/6 mice (body weight of 17-20 g; tumor size 
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of 4-5 mm in diameter) were intraperitoneally administrated with 100 mg of BSH per 1 kg of 
body weight. In 1 hour before euthanasia the mice were administrated with 3ǻ-thymidin (74 
kBq/g of body weigh); as control administration saline was used Excised tumors were used 
for preparation of cytological preparations. Melanocytes were determined as cells 
containing more than 5 granules of melanin (Alberts, 1989). Analysis of kinetics of DNA-
synthesizing cells was studied in preparations covered with “M” emulsion counting 3ǻ-
labelled melanocytes. These parameters were separately assessed for peripheral and central 
zones.  
2.8 Study of cell distribution through the cell cycle  
Alterations of the quantitative distribution through the cell cycle were also investigated. The 
distribution of tumor cells through the cell cycle was studied by flow DNA-cytofluorimetry 
on ICP-22 cytofluorimeter. 
The BSH distribution was investigated in B-16 melanoma bearing male C57Bl/6 mice. The 
mice had a body weight (BW) of 17-20 g, the tumor was subcutaneously transplanted. BSH 
was administrated intraperitoneously. 2 dose groups were injected with 50 and 150 mg/kg 
body weight on 9-11-th day after subcutaneous tumor inoculation. In 3, 12 and 24 hours 
after administration tumors were excised (3 samples per time point). Tumor samples were 
used for preparation of cell nuclei suspension. This suspension was dyed with mixture of 
ethidium bromide and mitramicin (1:1). 
2.9 Assessment of tumor growth 
During experiments with transplanted tumors three reciprocally perpendicular tumor’s 
diameters were daily measured and evaluated tumors volumes taking tumor’s shape as 
ellipse:  
 V=(/6). d1. d2 . d3 (1) 
Where V- tumor volume, d1, d2, d3 – linear dimensions of ellipsoid, cm 
For every temporary point tumor volume was normalized to it’s volume at the beginning of 
exposure (V0) and then V1/V0 against time from the beginning of exposure curves were 
constructed depending on every dose D and for every concrete mouse at adequate control 
for it (D=0). The parameters of tumor growth delay (Td) and of time of tumor’s volume 
duplication were evaluated from these curves as well as tumor growth index (2).  
 TGI=SE/SK (2) 
where: SE. – area under tumor growth curve of experimental group, Sк – area under tumor 
growth curve of experimental group.  
Area under tumor growth curve was calculated as following: 
 
1
1
1 2
n
i i
i
i
V V
S t
 

  (3) 
where Vi - tumor volume at ith measurement, 
n – number of measurements, 
ti – period between nearby measurements. 
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2.10 Drugs 
In our studies we have used the following medicines: [10B]-ВǾА (Khoknlov, 2001, Kulakov, 
2001, Kulakov, 2002) – 4-(dihidroxyboron)–L-phenilalane (BPA, KatChem, Chehia), Katchem, 
(Czechia), chemical purity of 98 % , degree of enrichment of 10В  99.7 %); borated ethers with 
D-fructose ([10B]-ВǾА-F) and D-galactose ([10B]-ВǾА-Gal); Na210B12H11SH - [10B]-BSH (Katchem, 
(Czechia) , chemical purity of 99 % ; degree of enrichment of 10В – 99.7 %; novel boron-
contained compound KUG-1 (this is manufacturing code of compound), chemical purity of 99 
% with natural boron and Dipentast® – Gd-DTPA based pharmaceutical with Gd content of 
28.11% and semi-elimination period from site of injection - 556 min.).  
The dogs were intravenously administrated with boron-containing compounds while the 
mice were administrated with boron-containing compounds intraperitoneally. Dipentast® 
was administrated intratumorally at uniform distribution (4-6 injection per tumor) both in 
NCT and PCT studies. 
3. Results of investigations 
3.1 Cell pharmacokinetics 
In the time interval from 1 to 12 h after the BSH administration relatively high boron content 
was in subcellular structures of tumor tissue. BSH was preferably accumulated in nuclei and 
mitochondria. (Table 1). These data suggest the BNCT with BSH might be more effective 
during time interval from 6 to 12 h after drug administration.  
 
Subcellular 
fractions 
Time after administration, h 
1 6 12 
Tumor Liver Tumor Liver Tumor Liver 
Nucleus 5.7 14 6.9 12.0 2.2 2.9 
Mitochondria 3.0 6.1 2.6 5.1 2.1 0.5 
Lysosomes 0.8 1.8 - 4.9 2.0 1.2 
Cytosol 1.5 1.2 0.2 1.5 0.2 1.3 
Table 1. 10В concentration in subcellular fractions of B-16 melanoma and liver in ǿ57Bl/6 
mice after BSH administration [10В µg/g] 
In the time interval from 24 to 48 h after the KUG-1 administration maximal boron content 
was in nuclear fraction. This concentration exceeded necessary and sufficient concentration 
for successful NCT. Boron content in other subcellular fractions was sufficient for 
therapeutic efficacy of NCT. (Table 2). Therefore boron subcellular distribution had 
confirmed clinical perspectives of KUG-1.  
 
Subcellular 
fractions 
Time after administration, h 
24 48 
Tumor Liver Tumor Liver 
Nucleus 8.13 9.1 10.9 9.3 
Mitochondria 4.59 3.17 4.29 4.56 
Lysosomes 3.48 3.83 4.58 13.5 
Cytosol 3.3 5.28 1.53 5.8 
Table 2. 10В concentration in subcellular fractions of B-16 melanoma and liver in ǿ57Bl/6 
mice after KUG-1 administration [10В µg/g] 
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3.2 Influence on cell cycle and kinetics of cell population of B-16 melanoma 
This research was devoted to study the influence of BSH – boron carrier at anticancer 
neutron capture therapy on cell population of murine melanoma B-16. It was proved that 
prevalent accumulation of tumor cells in synthetic and premitotic phases (S and G2/M) of 
cell cycle was caused by BSH effect. Probably this phenomenon of cell proliferation may be 
linked to compensatory population response on damaging factor of BSH (Ado, 1993). 
 The detected activity of the latter coupled with its ability to penetrate into the nucleus and 
mitochondria may be the reason for its efficacy in NCT of melanoma and opens new 
perspectives of the well known drug. These data are shown in tables 3, 4. 
 
Days after 
administration 
Peripheria Centre 
Control Experiment Control Experiment 
1 4.0±0.9 10.9±1.1 9.2±1.3 12.0±1.2 
2 13.1±1.2 15.3±1.3 16.7±1.3 8.8±1.0 
3 22.0±1.5 18.9±1.3 17.6±1.4 12.3±1.2 
Table 3. Quantity of melanocytes and labeled cells in peripheral and central zones of of В-16 
melanoma after BSH administration (100 mg/kg of body weight)  
 
Time after 
administration, h 
BSH, 
10В µg /kg 
BW 
Phase of cell cycle 
IG1 IIG1 S G2/M 
S+ 
G2/M 
3 
50 19.52.0 58.45.7 13.71.4 8.40.9 22.1 
150 20.12.1 57.24.5 14.31.5 7.90.8 22 
12 
50 16.71.5 56.45.4 8.91.1 18.72.0 27.6 
150 16.21.3 54.65.1 16.61.3 12.71.3 29.3 
24 
50 17.01.8 57.95.6 10.11.1 15.91.6 25.1 
150 16.01.4 57.05.5 14.31.3 12.71.3 27.0 
24 
Control 
(saline) 
20.11.9 59.25.7 14.01.5 6.70.7 20.7 
Table 4. Influence of ВSH on cell cycle of B-16 melanoma after BSH administration 
So, BSH is the drug of threefold action and this action allows to realize full potential of BSH.  
1. BSH is boron carrier to deliver boron into tumor and it’s vital structures. 
2. BSH stimulates proliferating cells (S+G2/M), increasing sensitivity for all types of 
irradiation.  
3. BSH influences on cell differentiation ( synthesis of melanin is index of cell 
differentiation for melanoma).  
The results of investigations demonstrated most efficacy of NCT during the first 24 h after 
BSH administration due to both subcellular distribution and influence on cell cycle.  
In further searching of new boron compounds for NCT it would be remembered that any 
chemical agent is probably active agent effecting on cell biology.  
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3.3 In vitro studies of photon capture therapy 
On the base of obtained results of ǺТТ-test and clonogenic test curves of dependence “ part 
of survived cells – exposition dose” were constructed. (Fig. 4 and Fig. 5). 
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Fig. 4. Cell survival for control and experimental groups (MTT-test data) at 3rd, 5th and  
7th days 
MTT-test data had shown equal parts of survived cells in both groups on 3-rd day. On 5-th 
day part survived cells in experimental group was essentially low and was retained at this 
level to 7-th day. RGG-test data had shown (Fig. 5) practically complete suppression of cell 
growth in experimental group even at 10 Gy. In control group significant quantity of cell 
colonies were observed. 
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Fig. 5. Cell survival for control and experimental groups (clonogenic test data) , 3-rd and  
5-th days. 
3.4 Radiobiological studies in vivo 
Studies of binary radio therapy in animals with potentially suitable for clinical application 
pharmaceuticals 
3.4.1 Boron neutron capture therapy 
The therapeutic efficacy of NCT was studied using two compounds: BSH and KUG-1 
containing 55% and 20% boron relatively. PGNAA data demonstrated that maximal boron 
content in tumor (12 μg/g of tissue) was achieved in 1 hour after BSH injection decreasing 
by 6 hours. Then this level was not varying for 48 hours. On the same time the compound 
rapidly eliminated from all tissues adjacent to tumor excluding skin. As result in 12-48 
hours interval there was sufficient for NCT ratio tumor/adjacent tissue including blood. 
The boron content suitable for NCT in the case of introduction of KUG-1 was accumulated 
in 24 hours and was constant not less then 15 hours. It should be noted that the total 
absorbed dose in tumor was determined from three major nuclear reactions - (n,γ)2H; 14N 
(n,p)14C; 10B (n,ά)7Li - contributing essential part in to absorbed dose at interactions 
between thermal neutrons and nuclides of living tissue and was equal to 95-97%. The time 
of tumor volume duplication (Тd) at NCT with BSH injection was increased to 14-15 days 
comparatively with 3-4 days for intact animals. In the case of Ph1 injection this time was 
prolonged to 8-10 days. The injection of Ph2 did not make this parameter differ from 
control meanings.  
 The increase of survival of treated mice was equal to 57% in the case of BSH administration 
and only 14% at KUG-1 administration in spite of KUG-1 accumulation coefficient was more 
than the same for BSH. It is caused with toxic side effect of KUG-1 (hepatic- and 
neurotoxicity). 
KUG1 is perspective for purposes of NCT but needs a development for eliminations of toxic 
side effects. Results of irradiation are shown in table 5 and in figure 6. 
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В-10-carrier for NCT KUG-1 BSH 
Absorbed dose in tumor from reaction on В-10,Gy 1.76 1.23 
Absorbed dose in tumor from reaction on N, Gy 0.42 0.79 
Absorbed dose in tumor from reaction on H, Gy  0.45 0.36 
Total absorbed dose in tumor  2.63 2.38 
Concentration of В-10 in tumor, initial, μg/g 11.3 8.3 
Concentration of В-10 in tumor, initial, μg/g 9.9 7 
Table 5. Results of thermal neutron irradiation mice bearing B-16 melanoma  
 
 
Fig. 6. Growth of transplanted B-16 melanoma in C57bl/6 after thermal neutron irradiation 
at presence of BSH and KUG-1 
3.4.2 Photon capture therapy 
On the base of obtained results of irradiation curves of tumor growth were constructed. 
(Fig. 7). Quantitative assessment of efficacy of each force was determined. (Table 6).  
 
Criterion Group 1 Group 2 Group 3 
Tumor growth delay time, days 15±1 8±1 - 
Tumor volume doubling time, days 16±2 11±1 - 
Tumor growth index (IG) 0.1±0.03 0.25±0.05 0.75±0.05 
Table 6. Quantitative parameters of effect assessment 
Obtained data demonstrate that local irradiation of melanoma containing Dipentast® 
resulted in significant inhibition of tumor growth in comparison with irradiation only. 
Administration of Dipentast® without consecutive irradiation didn’t result in expressed 
anticancer effect.  
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Fig. 7. Tumor volume growth kinetics for irradiated with Gd-DTPA injection group (▲), 
only irradiated group (■), only administered with Gd-DTPA group (∆), untreated group (□) 
3.5 Results of neutron capture therapy studies in dogs with spontaneous melanoma 
of the oral mucosa. Development of combined radiotherapy scheme on the basis of 
NCT and adjuvant immunotherapy  
The improvement of the technology of neutron capture therapy under the condition of 
nuclear reactors, conduction of detailed studies with the purpose of comparative evaluation 
of effectiveness of different variants of neutron capture technology and traditional methods 
of treatment is an important and topical clinical task. The conduction of preclinical studies 
will permit to choose the most efficient scheme of treatment of melanoma, since melanoma 
of the oral mucosa in dogs may be regarded as a correct model of human melanoma. 
The studies on effectiveness of BNC technology in treatment of spontaneous melanoma of 
canine oral mucosa have been conducted for several years. The preclinical study of neutron 
capture therapy on dogs with the diagnosis of oral mucosa melanoma has yielded the 
following results. 
In group I of the animals which did not receive any treatment, the average animal life 
expectancy was 38±13.6 days. 100% of the animals were euthanized due to their severe 
condition. The reason for euthanasia of such animals was local propagation of the tumor 
and systemic metastasis.  
In the group of animals who underwent surgical removal of the oral mucosa tumor, 100% 
recurrence occurred within the period of 26 ±12.5 days. In group III where the animals 
received traditional radiotherapy, stabilization of tumor growth was seen in 75% of cases, 
partial regression in 12.5% of animals and complete regression - also in 12.5% of animals. In 
100% of cases resumption of tumor growth within 30±5.5 days was observed. 
Thus, both at surgical treatment and at radiotherapy recurrence occurred in 100% of cases. 
The statistical analysis showed that the duration of the recurrence-free period at the use of 
these methods of treatment was in fact equal.  
This indicates that surgical treatment and radiotherapy are virtually low-effective methods 
of treating melanoma of oral mucosa in dogs at stage II-III of btumor process. This probably 
can be explained by the specific location of the tumor when it is impossible to perform 
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radical removal of the tumor. At these stages of tumor process the tumor size appears to be 
sufficiently large.  
To evaluate effectiveness of neutron capture radiotherapy, that is, NCT, the results obtained 
were compared to the animals subject to the action of neutron bundle alone. In this group 
(IV, n=5) partial regression was attained in 80% of cases, and complete regression - in 20% of 
cases. In 100% of cases the continued growth of the tumor within 101±28.8 days was also 
diagnosed. 
In group V, where irradiation with neutron bundle was performed with a preliminary 
administration of boron agents, that is, BNCT, complete tumor regression was possible to be 
attained in 78% of cases. (Fig. 8) At BNCT, in cases of complete tumor regression no 
recurrence was observed. The absence of recurrence in complete tumor regression proves 
complete destruction of melanoma cells in the primary tumor focus.  
In this study the boron product was administered by two routes: intravenously and 
regionally into the artery feeding the tumor. Having analyzed the results obtained, we got 
sufficiently significant data on that the route of the product administration exerts no effect 
on NCT effectiveness. Thus, during further studies of BNCT it is possible to administer 10В 
BFA intravenously that facilitates conduction of the BNCT procedure. 
During conduction of NCT with Dipentast®, that is, GdNCT (group VI), somewhat other 
results were obtained as compared to BNCT. First, tumor regression took place more slowly 
in at GdNCT comparing to BNCT, and complete tumor regression was noted only in 46% of 
cases (Fig.9). In 66.7% of animals recurrence of the tumor was seen 1067.5 days after the 
procedure of GdNCT. Nevertheless, the effect of irradiation at GdNCT was sufficiently high 
that suggested a possibility of development of an effective technology of melanoma 
treatment on the basis of GdNCT. 
Since so far a small number of studies on GdNCT was conducted and there are no data on 
the optimal concentration of gadolinium inside the tumor which is necessary to achieve the 
tumoricide dose, we studied the GdNCT effect at different doses of gadolinium in tumor. 
The studied range of concentrations was from 10 mg/cm3 to 100 mg/cm3. During the 
clinical trial the regularity was determined at which the best clinical effect of GdNCT was 
observed at the gadolinium concentration in tumor of up to 12 mg/cm3.  
We also conducted the study on investigating distribution of the power of total dose 
depending on the gadolinium concentration inside tumor. Such study was performed on the 
basis of the developed model of GdNCT (1). 
The study of total dose rate distribution during GdNCT at different concentration showed 
that at the gadolinium concentration over 12 mg/cm3 the total dose in the tissue sharply 
decreases by several times. So, at concentrations of 6-12 mg/cm3 the total dose power at the 
depth of 0.5 cm of tissue is 150-200 cGy/min and does not increase with the growth of the 
gadolinium concentration in target (Fig. 10). Such effect is due to the fact that isotopes of 
gadolinium 157Gd (the content in the natural element 15.68%) have high sections of capture 
of thermal neutrons. That causes an increase of absorption of thermal neutrons during 
GdNCT at high concentrations of gadolinium products. The so-called "shielding effect" 
occurs. 
Thus, the analysis of distribution of the total dose, by using the solving of the equation of 
transfer of neutrons and photons by the method of discrete ordinates according to the 
RADUGA-5 program, showed that the optimal concentration of 157Gd is within the range of 
6-12 mg of Gd in 1 cm3 of tumor. These conclusions help to optimize subsequently the 
process of GdNCT for achieving the maximum result. 
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A.    B. 
Fig. 8. BNCT Results of spontaneous melanoma of the oral mucosa: A - Melanoma before 
BNCT, B - 2 weeks after procedure BNCT. Full Tumor regression 
 
    
A.    B. 
Fig. 9. GdNCT Full regression of melanoma. A – Oral Melanoma, B - 1,5 months after 
GdNCT 
 
 
Fig. 10. Tumor dose distribution in different 157Gd concentration. 
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Thus, the clinical results agree entirely with the further studies on investigating distribution 
of the total dose power depending on the gadolinium concentration inside tumor.  
Comparing the time of recurrence in control and at GdNCT we found that the time of 
recurrence at GdNCT (1067.5 days) significantly exceeds the time of recurrence at surgery 
(2612.5 days) and at traditional gamma-therapy (305.5 days). Such advantage of the 
GdNCT method comparing to traditional therapy is explained by a high local dose of 
irradiation of 80-100 Gy per the irradiated target. 
The differences in the results of BNCT and GdNCT, in our opinion, may be explained by 
two reasons:  
the differences in the pharmacokinetic properties of the used products - 10В-boron 
phenylalanine during BNCT and the complex of gadolinium with DTPA during GNCT; 
different products of nuclear and physical reactions of nuclei of 10В and Gd with thermal 
neutrons.  
During BNCT there is a selective accumulation of 10В-boron phenylalanine inside the tumor 
cells. The ratio of 10В concentrations in the tumor and in normal tissues is not less than 2.5. 
The run of alpha-particles which are formed during irradiation is commensurable with the 
cell diameter, and the nuclei of 6Li – less than the cell diameter. Therefore secondary 
radiation affects predominantly tumor cells, by which a high effect of BNCT effect is 
achieved. And in the given study during BNCT we observed degree 1-2 of local radiation 
reactions. 
During GdNCT the used product with gadolinium - Dipentast® is mainly in the 
intercellular space, and accumulation of the product inside tumor is achieved only by 
intratumoral administration of the product. As a result of absorption of thermal neutrons 
by the nuclei of 157Gd there are formed high-energy gamma-quanta, low-energy electrons 
and roentgen radiation. It is secondary radiation that causes death of tumor cells. 
However, the character of secondary radiation leads to affection of healthy tissues as well. 
At the use of GdNCT degree 2 of local radiation reactions was diagnosed in all animals, 
and in one case - stage 4.Such difference in the mechanism clinically should manifest itself 
in an increase of side effects on healthy tissues during GdNCT. Indeed, during GdNCT 
the degree of radiation lesions of healthy tissues was somewhat higher (degrees 2 and 4 of 
local radiation reactions) than at irradiation with neutrons and during BNCT (degree 1-2 
of local radiation reactions). 
An increase of recurrence rate at GdNCT even in complete regression of tumor shows that 
at GdNCT it is not always possible to achieve death of all tumor cells. One of the reasons 
of this result may be the excessive concentration of 157Gd inside tumor. As natural 
gadolinium has the section of neutron capture two orders higher than boron has, at its 
excessive concentration in tumor the effect of screening on the tumor surface may occur 
that does not allow to achieve destruction of cells in a deeper layer. During further 
studies, at improvement of GNCT technology, it is necessary to administer gadolinium 
product in such way so that the gadolinium concentration in tumor tissue would not 
exceed 12 mg/cm3. 
Despite the conducted treatment, in all animals there was recorded systemic metastasis into 
the lungs, that is, despite local cure of oral mucosa melanoma, the further generalization of 
tumor process could not be avoided. Thus, NCT is effective comparing to other methods for 
local treatment of the primary tumor focus but influences in no way the process of 
formation of metastases. Therefore the task of this study was not only to evaluate NCT 
effectiveness during treatment of the primary tumor focus, also development of the 
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multimodality treatment aimed at both the primary tumor focus and prevention of quick 
metastasis of tumor. We formed two groups of animals - groups VII and VIII in which we 
determined life expectancy. These groups embraced the animals at one stage of tumor 
process in which complete regression was achieved as a result of NCT. In this study the 
adjuvant therapy influence on life expectancy of dogs with oral cavity melanoma (group 
VII) was investigated by using Ronkoleukin®. For inclusion into the scheme of treatment of 
melanoma on the basis of BNCT and GdNCT as the means hampering the process of 
metastasis, the Russian agent Roncoleukin® was chosen which is an immunostimulator, it 
enhances the antibacterial, antiviral, antifungal and antitumor immune response.  
We managed to carry out the study on a small group of animals, but the results obtained 
show significantly that life expectancy at conduction of immunotherapy increase on the 
average by three times. So, in the study group of the animals which received successful 
BNCT at stage II of tumor process and also receive adjuvant immunotherapy, the average 
life expectancy was about 305 days. In group VIII where BNCT was conducted without 
immunotherapy, the average life expectancy was 113 days.  
Thus, in cases of successful NCT at concomitant conduction of immune therapy we 
observed the maximum life expectancies, and most such animals were long-living ones.  
The studies performed by us have shown that treatment of oral mucosa melanoma should 
be of multimodality character and be aimed at both combating the primary tumor focus and 
remote metastases. 
During conduction of NCT it is necessary to attain complete regression of tumor, it is in 
these cases that the maximum life expectancies may be reached.  
This approach to the diseases, namely the combination of NCT and adjuvant immune 
therapy permitted us to gain the maximum results in treating melanoma. 
In this chapter the results of complex method of oral canine melanoma are shown, but also 
we studied the possibility of NCT combination with other methods for canine osteosarcoma 
treatment. Induction chemotherapy, intraarterious administration of BPhA, bone resection, 
extracorporal BNCT of bone fragment, radiated bone implantation and adjuvant 
chemotherapy were included in treatment scheme (Fig. 11). 24 hours after operation dog can 
lean on the leg. 2.5 months after operation, results of biopsy showed absence of tumor cells 
in replanted bone. X-ray imaging showed full consolidation of replanted bone with maternal 
bone, without carcinogenesis signs (Fig. 11, 12), Total life span of the dog was 2.5 years 
without recurrence. 
Results of highly malignant tumors treatment show that, instead of high metastatic activity 
and low traditional methods efficacy , it is possible to achieve high therapeutic efficacy with 
application of complex treatment scheme on the basis of NCT. 
4. Conclusion 
There is a large world positive experience of BNCT clinical application in combined 
treatment of more than 300 patients with brain tumors (Japan, USA, EU countries) and more 
than 30 patients with melanoma, including metastatic melanoma (Japan, USA), which shows 
the prospects for future development and optimization of this type of binary therapy. 
According to Japanese clinical data for 1968-1996, average life span of patients with brain 
tumors was from 640 till 1811 days, depending on histological type of tumor, without strong 
mental disorders. 6 patients after BNCT live more than 10 years. Average life span of such 
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Fig. 11. BNCT of primary osteosarcoma IIb stage. A, B – Roentgenoscopy before operation; 
C, D - Roentgenoscopy 2.5 months after surgery.  
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Fig. 12. A dog on walk 2.5 months after BNCT. Surgery region is marked in yellow 
patients after traditional methods of treatments was 8-10 months. Doctor Nakagawa Y., 
taking into consideration BNCT opportunities and analyzing his own clinical experience, 
supposes, that BNCT is the best method for malignant brain tumors treatment, which needs 
further development of neutron beams and 10B-containing drugs (Nakagawa & Hatanaka, 
1997; Nakagava et. al., 2003). Preliminary analysis of melanoma treatment clinical results 
shows, that more than 2 years life span for patients with melanoma was 78%, treatment can 
be succeed in T3-4 N0M0 melanoma in more than 90% of patients. (Mishima 1996; Busse et al., 
1997; Barth et al., 2005). 
Achieved by Russian scientists results prove the advantages of BRT in comparison with 
traditional methods of treatment. ВǾА is more effective substance for BNCT than BSH and 
KUG-1. Full tumor regression was reached in 80% of cases with application of BNCT, and in 
the group of GdNCT full tumor regressions was in 50% of dogs with oral cavity melanoma, 
while the application of traditional gamma-therapy provides only 12,5 % of full tumor 
regression. Complex therapy, which combines BNCT with adjuvant immunotherapy with 
Ronkoleukin® (Interleukin-2) can increase the total life span more than 3 times. To compare 
with human life span we can speak about possibility of 5-10 years recurrence-free period for 
humans. As canine melanoma is the correct model of human melanoma, such complex 
method of treatment significantly more effective than traditional methods of treatment One 
of the reason of BNCT efficacy with BSH is the capability of BSH to penetrate into the cell 
nucleus and mitochondrions. This fact opens new prospects for future application of BSH in 
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BNCT. Complex treatment scheme, which combines traditional methods of treatment with 
BRT can significantly improve malignancy treatment. 
Therapeutic possibilities of BRT are note finally defined, but this method of treatment has 
low cost and it can be easily installed and transported to other hospital. It makes us to 
intensify the studies for effective BRT technologies creation, putting more attention for 
creation of specific pharmaceuticals, which can accumulate in the tumor with tumor/normal 
concentration gradient more than 3. To minimize resources for new pharmaceuticals 
selection for further studies we apply developed screening scheme. 
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